CAR-T/CAR-NK Target Assessment Service (ISH)
Chimeric antigen receptor (CAR) T cell therapy is highly effective in treating hematologic malignancies, and major efforts are being made to achieve similar efficacy in solid tumors. Two landmark events occurred for CAR-T cell therapy in 2017: two anti-CD19 CAR-T cells were approved for the therapy of acute lymphoblastic leukemia (ALL) and relapsed or refractory large B-cell lymphoma,...
0 Comments 0 Shares 975 Views